Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1943-1944, 2008; 10.1373/clinchem.2008.117382
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, M. D.
(Clinical Chemistry. 2008;54:1943-1944.)
© 2008 American Association for Clinical Chemistry, Inc.

Editorials

What Kind of Stroke Is It?

Michael D. Hill

Departments of Clinical Neuroscience, Community Health Sciences, Medicine, and Radiology, Calgary Stroke Program, Hotchkiss Brain Institute at the University of Calgary, Calgary, Alberta, Canada

Address correspondence to this author at: University of Calgary, Rm 1242A, Foothills Medical Centre University of Calgary, 1403-29th Street NW, Calgary, AB, Canada T2N 2T9, Fax 01-403-2832270, E-mail michael.hill@calgaryhealthregion.ca

The first 20% of the full text of this article appears below.

The search for protein biomarkers in peripheral blood to aid in the diagnosis of stroke and the prediction of prognosis after stroke and risk of future stroke is an active area of investigation. Although some markers, such as S100b and neuron-specific enolase, have been shown to have prognostic value in ischemic stroke (1)(2), no biochemical markers have proven to be really useful in routine clinical practice. In this issue of Clinical Chemistry, Nybo and associates present similarly discouraging data for osteoprotegerin as a potential stroke biomarker (3). Why are we continuing to see lack of demonstrated clinical utility in studies for stroke biomarkers? Should the search for biomarkers for stroke be abandoned?

Some answers may lie in the deceptively simple question, what is a stroke?

Stroke is currently defined as a disruption of brain function due to a vascular insult, with symptoms lasting 24 h or more. This definition, now old, is in flux and in truth, our understanding of stroke . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.